Latest Prostate cancer Stories
Conference call to be held on Thursday, May 2 at 4:30pm Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, May 2, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two product candidates, custirsen and OGX-427, and announced first quarter 2013 financial results. OGX-427 Program Update In January 2013, the Company initiated the ORCA(TM) (Ongoing Studies Evaluating Treatment Resistance...
UCL's Mark Emberton, MD, to Direct Premier Training Center for the Use of Advanced Imaging Capabilities to Localize Cancer and Deliver HIFU Treatment Using Tissue Preserving Techniques CHARLOTTE, N.C., May 2, 2013 /PRNewswire/ -- SonaCare Medical, a global leader in minimally invasive HIFU technologies, announced today that it has partnered with University College London (UCL) to create a HIFU Center of Excellence. The Center of Excellence will provide physician training and...
Sonatherm is the Only Laparoscopic HIFU Device Cleared for Ablating Soft Tissue in the U.S. CHARLOTTE, N.C., May 2, 2013 /PRNewswire/ -- SonaCare Medical, a leader in minimally invasive high intensity focused ultrasound (HIFU) technology, announced today that it will launch the FDA-Cleared Sonatherm(®) HIFU Surgical Ablation System at the the 108(th) Annual Meeting of the American Urological Association (AUA), in San Diego, May 4-8, 2013 (booth #3611). A state-of-the-art...
May is Skin Cancer Awareness Month, an opportunity to increase public understanding of the prevalence, prevention and treatment of the most common type of cancer diagnosis. Rolling Meadows, Ill. (PRWEB) May 01, 2013 More than 1 million Americans are diagnosed with skin cancer each year – more than cancers of the prostate, breast, lung, colon, uterus, ovaries and pancreas combined. As warm and comforting as the sun feels on the skin in the moment, it’s just as dangerous in the long...
Complete Results from UCSF-Led Validation Study to be Presented Earlier that Day at the American Urological Association (AUA) Annual Meeting in San Diego REDWOOD CITY,Calif., May 1, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will host an investor webcast and conference call to discuss the positive development and clinical validation study results of its biopsy-based Oncotype DX prostate cancer test on Wednesday, May 8, 2013 at...
Pancreatic Cancer Becomes the Fourth Tumor Type Evaluated as Part of the OGX-427 ORCA(TM) Program, In Addition to Bladder, Lung and Prostate Cancers BOTHELL, Wash. and VANCOUVER, British Columbia, May 1, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Rainier(TM) trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating OGX-427 in combination with ABRAXANE(®) (paclitaxel protein-bound...
Cancer cells are wily, well-traveled adversaries, constantly side-stepping treatments to stop their spread. But for the first time, scientists at the University of Michigan have decoded the molecular chatter that ramps certain cancer cells into overdrive and can cause tumors to metastasize throughout the body. Researchers have long known that tumors recruit healing cells, which is a major reason why cancer is so difficult to thwart. This is the first known study to explain the molecular...
SmartTarget Offers a Clinically Tested and Practical Solution for MRI-Ultrasound Fusion CHARLOTTE, N.C. and LONDON, April 30, 2013 /PRNewswire/ -- SonaCare Medical, a global leader in minimally invasive High-Intensity Focused Ultrasound (HIFU) technologies, and UCL Business PLC (UCLB), a leading technology transfer company that supports and commercializes research and innovations from UCL (University College London), today announced a partnership to integrate SmartTarget image...
Industry Veteran to Lead Metamark Genetics in Commercialization of Novel Prognostic Tests for Prostate and Other Cancers CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Metamark Genetics, Inc., a leader in the discovery of novel molecular prognostic and diagnostic tests for cancer, today announced that industry veteran Shawn M. Marcell has been named the company's new president and chief executive officer. Mr. Marcell succeeds interim executive Michael Kauffman, M.D., who will...
'This study confirms that VEGF is not a path forward to tackling this disease' The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers from the Department of Radiation Oncology at Thomas Jefferson University Hospital and other institutions found in a retrospective study published online April 25 in the journal BMC Radiation Oncology. VEGF, or vascular endothelial growth factor, induces blood...
